Norrie Russell has joined Invitrogen as vice president and general manager of its functional genomics strategic business unit, the company said last week. Most recently, he was president and CEO of Aviva Biosciences. Prior to that, he was president and CEO of Lynx Therapeutics. Russell holds a PhD in physiology from Glasgow University in Scotland.
Peter Wagner has been promoted to CEO of Zyomyx, the company said this week, replacing Robert Monaghan. Wagner, a company co-founder, has been Zyomyx’s chief technology officer since 1998.
Paul James has resigned as senior vice president of commercial operations of Biacore International, the company said this week. His resignation was unexpected and “due to personal family reasons,” the company said in a statement. Biacore his currently searching for a successor and plans to fill James’ post by early 2005. In the meantime, company CEO Erik Wallden will be responsible for all of Biacore’s commercial operations.
Alan Hollingsworth has joined the scientific advisory board of Power3 Medical Products, the proteomics company said this week. He is the medical director at Mercy Women’s Center in Oklahoma City.
John Bergeron will receive the McLaughlin Medal from the Royal Society of Canada, the Canadian Academy of the Sciences and Humanities, at the society’s awards banquet on Nov. 20. He is a professor and chair of anatomy and cell biology at McGill University and director of the Montreal Proteomics Network. He is also the current president of HUPO. Bergeron holds a doctorate from Oxford University and an undergraduate degree in biochemistry from McGill University.